Regulatory Celcuity gains FDA approval for closely watched breast cancer drug BioPharma DiveStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk.OncologyRead full story pharminent July 15, 2026 (Last updated: July 20, 2026) BioPharma Dive Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Oncology Read full story Post navigation Previous: AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drugNext: J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
